| FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR Patent applications |
| Patent application number | Title | Published |
|---|
| 20120128643 | GENE VECTOR - A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell. | 05-24-2012 |
| 20120027802 | USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES - It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed. | 02-02-2012 |
| 20110218234 | GENE VECTOR FOR INDUCING TRANSGENE-SPECIFIC IMMUNE TOLERANCE - A gene vector adapted for transient expression of a transgene in a peripheral organ cell comprising a regulatory sequence operably linked to a transgene wherein the regulatory sequence prevents or reduces expression of said transgene in hematopoietic lineage cells. | 09-08-2011 |
| 20110158957 | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases - Disclosed herein are methods and compositions for inactivating TCR genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. Disclosed herein are also methods and compositions for expressing a functional exogenous TCR in the absence of endogenous TCR expression in T lymphocytes, including lymphocytes with a central memory phenotype. Polynucleotides encoding exogenous TCR, vectors comprising polynucleotides encoding exogenous TCR and cells comprising polynucleotides encoding exogenous TCR and/or cells comprising exogenous TCR are also provided. | 06-30-2011 |
| 20110117226 | USES OF CONGLUTIN-GAMMA - An enriched conglutin-γ protein extract from lupin seeds having a % by weight of conglutin-γ between 10 and 30%, or a conglutin-γ protein, or functional derivatives thereof for use as a medicament, as food integrator or diet supplement or integrator. | 05-19-2011 |
| 20110076234 | PEPTIDES COMPRISING AN ISODGR MOTIF - Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif. | 03-31-2011 |
| 20100323385 | NITROGEN INDEPENDENCE IDENTIFIES A HIGHLY MALIGNANT POPULATION OF TUMOR STEM CELLS - The present invention is directed to a method for isolating and establishing Growth Factor-Independent (GF-I) Tumor Stem Cells (TSCs) from tumor biopsies or tumor cell lines consisting in culturing cells in serum-free mitogen-free culture medium. The method discloses cell growth in a culture medium, which does neither comprise serum, nor EGF (Epidermal Growth factor) and FGF-2 (Fibroblast Growth Factor), nor both, nor EGF or FGF-2 derivatives with the same mitogenic characteristics of the parent molecules. According to a preferred embodiment, the method is directed to the isolation of Tumor stem cells (TSCs) from glioblastoma multiforme (GBM) or from other brain tumors or brain tumor cell lines. GF-Independent TSCs can be identified and expanded in vitro providing a homogeneous population of multipotent, self-renewing and highly tumorigenic Growth Factor-Independent TSCs, distinguishable from tumor stem cells derived with other methods, grown in parallel, for the above characteristics. The invention also encompasses therapeutic methods based on Tumor Stem Cells isolated as described. | 12-23-2010 |
| 20100297137 | Hematopoietic Lineage Cell Specific Protein (HS1) as a Marker for Lymphoid Malignancy - Use of a phosphorylated form of hematopoietic-lineage-cell-specific-protein-1 (HS1) as a prognostic or diagnostic marker for a Lymphoid Malignancy, a disease in which B cell receptor stimulation is dysregulated or disease characterised by B lymphocyte proliferation. | 11-25-2010 |
| 20100041737 | Gene Vector - A gene vector comprising a miRNA sequence target. | 02-18-2010 |
| 20100041145 | TOLEROGENIC DENDRITIC CELLS, METHOD FOR THEIR PRODUCTION AND USES THEROF - The present invention relates to a tolerogenic dendritic cell population (Tr-DC) capable of generating a population of T cells having regulatory activity, method of production and uses thereof. Furthermore, soluble HLA-G promotes the differentiation of a population of T cells with regulatory activity. | 02-18-2010 |
| 20090317909 | SKELETAL MUSCLE PERIANGIOBLASTS AND CARDIAC MESANGIOBLASTS, METHOD FOR ISOLATION AND USES THEREOF - The present invention discloses the isolation and characterization of cells isolated either from adult skeletal muscle or from adult cardiac muscle. These cells are used for the treatment of muscular disorders including muscular dystrophy and cardiopathics, respectively. | 12-24-2009 |
| 20090092663 | Tumor-targeted drug delivery systems and uses thereof - The present invention relates to targeted delivery systems for delivering therapeutic agents to tumor. The invention further relates to methods of delivering a therapeutic agent to a tumor for the prevention and treatment of cancer by killing tumor cells and tumor-associated endothelial cells. In particular, the present invention provides a tumor-targeted drug delivery system comprising a NGR-containing molecule linked to a delivery vehicle encapsulating a therapeutic agent, preferably a drug, such as a cytotoxic agent or a chemotherapeutic agent. Specifically, the delivery systems of the present invention are capable of delivering an increased amount of therapeutic agent to a tumor as compared to other delivery systems. In particular, the delivery systems of the present invention are capable of accumulating a higher amount of therapeutic agent in a tumor, or in the vicinity of a tumor cell or tumor-supporting cell, resulting in exposure of the tumor cell and tumor-associated endothelial cell to therapeutic levels of the agent for a longer period of time as compared to other delivery systems. The present invention also describes pharmaceutical compositions comprising the delivery systems of the present invention. The present invention further relates to a tumor treatment comprising an increased amount of therapeutic agent delivered by the system of the present invention as compared to other delivery systems. The delivery systems and pharmaceutical compositions can be administered to a subject, preferably a human, alone or in combination, sequentially or simultaneously, with other prophylactic or therapeutic agents and/or anti-cancer treatments. | 04-09-2009 |
